TITLE:
Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost
AUTHORS:
Italo Giuffrè
KEYWORDS:
Bimatoprost 0.01%, Bimatoprost 0.03%/Timolol 0.50% Fixed Combination, Glaucoma, OSDI, Timolol 0.50%
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.4 No.2,
May
14,
2014
ABSTRACT: Objectives: To compare ocular surface changes induced via glaucoma
treatment in patients using fixed combinations of bimatoprost 0.03%/timolol
0.50%, timolol 0.50% or bimatoprost 0.01% eye drops. Methods: This is a
prospective, one center, open-label clinical trial. It was performed on 60
glaucoma patients between 01-01-2012 and 12-31-2012. These patients were
randomly divided in three subgroups: bimatoprost 0.03%/timolol 0.50% fixed
combination, timolol 0.50% and bimatoprost 0.01%. The Ocular Surface Disease
Index (O.S.D.I.) was evaluated in all the glaucomatous patients of the three
subgroups at basal time and after 6 and 12 months. All the results were
statistically evaluated by Student t-test and one-way ANOVA. The results were
considered statistically significant if p ost 0.01% and bimatoprost 0.03%/timolol 0.50% patients
(p = 0.05) and between bimatoprost 0.01% and timolol 0.50% eye drops alone (p =
0.049). Conclusions: This is a clinical trial based not on the hypotonising
effect of these drugs but on their tolerability. The drug which showed the best
tolerability is bimatoprost 0.01%.